SEC 13F Intelligence

Managers / Q3 2021

KNOTT DAVID M

CIK 0000808722

Reported Value
$275M
Q3 2021
Positions
197
Filings on Record
12
2019–present window
Filed
Nov 12, 2021
original filing

Summary

Knott David M reported $275M in U.S.-listed holdings across 197 positions for Q3 2021.

Its largest position, Calumet Specialty Products Partners, represents 10.1% of the portfolio.

Compared with Q2 2021, the fund opened 21 new positions and exited 18.

Portfolio Metrics

Turnover
+23.6%
vs prior filed quarter
Top-10 Concentration
+44.2%
share of reported value
Largest Position
+10.1%
Calumet Specialty Products Partners
New / Exited
21 / 18
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $213MQ4 ’18Q1 ’19: $251MQ2 ’19: $237MQ2 ’19Q3 ’19: $238MQ4 ’19: $247MQ4 ’19Q1 ’20: $158MQ2 ’20: $183MQ2 ’20Q3 ’20: $170MQ4 ’20: $221MQ4 ’20Q1 ’21: $234MQ2 ’21: $281MQ2 ’21Q3 ’21: $275Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 47.4%Other: 36.0%MLP: 11.2%Ltd Part: 4.6%REIT: 0.5%Other: 0.3%
  • Common Stock · 47.4% · $130M
  • Other · 36.0% · $99M
  • MLP · 11.2% · $31M
  • Ltd Part · 4.6% · $13M
  • REIT · 0.5% · $1M
  • Other · 0.3% · $808,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Greenidge Generation Holdings Inc.NEW+448.8K448.8K+$11M$11M
Coliseum Acquisition CorpNEW+984.8K984.8K+$10M$10M
Greenidge Generation Holdings Inc.NEW+224.0K224.0K+$6M$6M
Coliseum Acquisition Corp. WtsNEW+495.0K495.0K+$6M$6M
B.Riley Principal 250 Merger Corp.NEW+350.0K350.0K+$3M$3M
Horizon Acquistion CorporationNEW+210.1K210.1K+$2M$2M
Medicus Science Acquisition, Corp.NEW+200.0K200.0K+$2M$2M
INCYIncyte CorporationNEW+26.5K26.5K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Calumet Specialty Products Partners, LPCommon10.06%$28M3.50M
2APOEURApollo Global Management, Inc.history →Common5.60%$15M250.0K
3GOOGAlphabet Inc-Cl Chistory →Common5.42%$15M5.6K
4FTAIEURFortress Trans & Infrastructure Inv. LLChistory →Common4.59%$13M497.7K
5LGNDLigand Pharmaceuticals Incorporatedhistory →Common3.80%$10M75.0K
6UPLDEURUpland Software, Inc.history →Common3.65%$10M300.0K
7Coliseum Acquisition CorpCommon3.47%$10M984.8K
8KDMNKadmon Holdings, Inc.history →Common3.13%$9M989.5K
9MDWTUSDMidwest Holding Inc.history →Common2.40%$7M170.0K
10Greenidge Generation Holdings Inc.Common2.08%$6M224.0K
11Coliseum Acquisition Corp. WtsCommon2.07%$6M495.0K
12African Gold Acquistion Corp. WarrantsCommon1.88%$5M450.0K
13PFEPfizer Inc.history →Common1.79%$5M114.5K
14Glass Houses Acquisition Corp.Common1.78%$5M500.0K
15Twelve Seas Investment Company IICommon1.77%$5M500.0K
16Kennedy-Wilson Holdings, Inc.Common1.60%$4M210.0K
17EBCEastern Bankshares Inchistory →Common1.40%$4M190.0K
18REGNRegeneron Pharmaceuticals, Inc.history →Common1.32%$4M6.0K
19TREURTrillium Therapeutics Inc.history →Common1.27%$3M198.7K
20Live Oak Mobility Aquisition Corp.Common1.27%$3M360.2K
21FSKFS KKR Capital Corp.history →Common1.24%$3M154.7K
22B.Riley Principal 250 Merger Corp.Common1.23%$3M350.0K
23Danimer Scientific, Inc.Common1.19%$3M200.0K
24Kairos Acquisition Corp.Common1.16%$3M331.0K
25KKRKKR & Co. Inc.history →Common1.11%$3M50.0K
26Avadel Pharmaceuticals plcCommon1.07%$3M301.9K
27Glass Houses Acquisition Corp. WarrantsCommon1.04%$3M250.0K
28UTHUnited Therapeutics Corporationhistory →Common1.03%$3M15.3K
29BMYBristol-Myers Squibb CompanyCommon0.91%$3M42.4K
30ABAllianceBernstein Holdings PL Unit Ltd.Common0.88%$2M49.0K
31Horizon Therapeutics Public Ltd. CompanyCommon0.80%$2M20.0K
32Horizon Acquistion CorporationCommon0.76%$2M210.1K
33CLDNEUREiger BioPharmaceuticals, Inc.Common0.76%$2M312.5K
34JPMJP Morgan ChaseCommon0.73%$2M12.2K
35Tastemaker Acquisition Corp.Common0.72%$2M200.0K
36Medicus Science Acquisition, Corp.Common0.71%$2M200.0K
37INVAInnoviva, Inc.Common0.70%$2M115.3K
38Twelve Seas Investment Company II WarrantsCommon0.70%$2M166.7K
39ZGNXEURZogenix, Inc.Common0.69%$2M124.7K
40INCYIncyte CorporationCommon0.66%$2M26.5K
41B. Riley Principal 150 Merger Corp.Common0.61%$2M173.0K
42TGTXTG Therapeutics, Inc.Common0.60%$2M49.6K
43CHRSCoherus Biosciences, Inc.Common0.60%$2M102.6K
44Kairos Acquisition Corp. WarrantsCommon0.58%$2M139.3K
45uniQure N.V.Common0.54%$1M46.8K
46XENEXenon Pharmaceuticals Inc.Common0.52%$1M94.5K
47AUPHAurinia Pharmaceuticals Inc.Common0.51%$1M62.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$275M197Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$281M195Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$234M166May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$221M145Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$170M135Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$183M127Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$158M156May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$247M152Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$238M157Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$237M148Aug 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$251M143May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$213M133Feb 12, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.